Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Neoadjuvant BMS-813160/nivolumab/GnP was well tolerated and seems to achieve comparable ORR and resectability with historical data; however, with prolonged PFS and OS in LA-PDAC patients, warranting a larger phase II study with a more efficacious CCR2-targeted therapeutic.
Authors
- Katrina S. Pedersen (ORCID: https://orcid.org/0000-0003-2793-6901)
- Rama Suresh (ORCID: https://orcid.org/0000-0003-1637-9994)
- Andrea Wang‐Gillam (ORCID: https://orcid.org/0000-0003-0458-7614)
- Peter Oppelt (ORCID: https://orcid.org/0000-0002-3557-8449)
- Jingxia Liu (ORCID: https://orcid.org/0000-0002-9434-7907)
- Emily G. Butka (ORCID: https://orcid.org/0000-0003-2615-3454)
- Ashley Frith (ORCID: https://orcid.org/0000-0001-9507-4122)
- Olivia Aranha (ORCID: https://orcid.org/0000-0003-3405-5694)
- Nicholas Boice (ORCID: https://orcid.org/0000-0002-3615-5325)
- Benjamin Tan (ORCID: https://orcid.org/0000-0003-1838-1182)
- Patrick Grierson (ORCID: https://orcid.org/0000-0002-0624-6699)
- Jennifer Spann
- David G. DeNardo (ORCID: https://orcid.org/0000-0002-3655-5783)
- Lee Ratner (ORCID: https://orcid.org/0000-0003-2744-7294)
- Kian‐Huat Lim (ORCID: https://orcid.org/0000-0002-2766-200X)
- Amberly Brown (ORCID: https://orcid.org/0000-0001-8300-5701)
- Faiz Ahmad (ORCID: https://orcid.org/0000-0002-0450-042X)
- John Baer (ORCID: https://orcid.org/0000-0002-8758-0030)
- Yongping Xu (ORCID: https://orcid.org/0009-0008-6333-8224)
- Crystal Wolf
Institutions
- Washington University in St. Louis (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-21
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1821
- Citations
- 7
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 7.32